Nicardipine vs. Saline injection as treatment for peyronie's disease: A prospective, randomized, single-blind trial

Journal of Sexual Medicine

Volumn 7, Issue 11, 2010, Pages 3743-3749

  Soh, Jintetsu ^a   Kawauchi, Akihiro ^a   Kanemitsu, Noriyuki ^a   Naya, Yoshio ^a   Ochiai, Atsushi ^a   Naitoh, Yasuyuki ^a   Fujiwara, Terufumi ^b   Kamoi, Kazumi ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Fujiwara Urological Clinic   (Japan)

Author keywords

Erectile Dysfunction; Intralesional Injection; Medical Therapy for Peyronie's Disease; Nicardipine

Indexed keywords

NICARDIPINE; PROSTAGLANDIN E1; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ECHOGRAPHY; HUMAN; HYPOTENSION; INJECTION SITE ECCHYMOSIS; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PEYRONIE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

EID: 78049474242     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01924.x     Document Type: Article

References (37)

1. Smith CJ, McMahon C, Shabsigh R. Peyronie's disease: The epidemiology, aetiology and clinical evaluation of deformity. BJU Int 2005;95:729-32.
2. Müller A, Mulhall JP. Peyronie's disease intervention trials: Methodological challenges and issues. J Sex Med 2009;6:848-61.
3. Hauck EW, Diemer T, Schmelz HU, Weidner W. A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 2006;49:987-97.
4. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F, SIMONA Study Group. Peyronie's disease: Prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol 2001;40:525-30.
5. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: Results of a large survey. BJU Int 2001;88:727-30.
6. Mulhall JP, Creech SD, Boorjian SA, Ghaly S, Kim ED, Moty A, Davis R, Hellstrom W. Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening. J Urol 2004;171:2350-3.
7. Kadioglu A, Tefekli A, Erol B, Oktar T, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002;168:1075-9.
8. Rhoden EL, Teloken C, Ting HY, Lucas ML, Teodósio da Ros C, Ary Vargas Souto C. Prevalence of Peyronie's disease in men over 50-y-old from Southern Brazil. Int J Impot Res 2001;13:291-3.
9. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's disease. J Urol 2006;175:2115-8; discussion 2118.
10. El-Sakka AI, Tayeb KA. Peyronie's disease in diabetic patients being screened for erectile dysfunction. J Urol 2005;174:1026-30.
11. Devine CJ. International Conference on Peyronie's disease advances in basic and clinical research. J Urol 1997;157:272-5.
12. Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994;151:1522-4.
13. Lee RC, Ping J. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J Surg Res 1990;49:463-6.
14. Gurdal H, Sara Y, Tulunay FC. Effects of calcium channel blockers on formalin-induced nociception and inflammation in rats. Pharmacology 1992;44:290-6.
15. Safarinejad MR. Comparison of Vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: A double-blind, placebo controlled, randomized study. J Urol 2007;178:1398-403.
16. Hellstrom WJ, Cockerham YR. Intralesional injection therapy for Peyronie's disease. J Sex Med 2009;6:1811-4.
17. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
18. Beers MH, Fletcher MB. The Merck Manual of diagnosis and therapy. 17th edition. West Point: Merck and Co.; 1999.
19. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): A Multidimensional Scale for Assessment of Erectile Dysfunction. Urology 1997;49:822-30.
20. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Peña BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999;11:319-26.
21. Cavallini G, Modenini F, Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007;69:950-4.
22. Winter CC, Khanna R. Peyronie's disease: Results with dermo-jet injection of dexamethasone. J Urol 1975;114:898-900.
23. Wegner HE, Andresen R, Knispel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997;32:190-3.
24. Judge IS, Wisniewski ZS. Intralesional interferon in the treatment of Peyronie's disease: A pilot study. Br J Urol 1997;79:40-2.
25. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: A prospective, single-center, non-placebo-controlled study. J Sex Med 2008;5:180-7.
26. Levine LA. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003;15(5 suppl):113-20.
27. Levine LA. Treatment of Peyronie's disease with intralesional verapamil injection. J Urol 1997;158:1395-9.
28. Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long-term single-blind study. Urology 1998;51:620-6.
29. Anderson MS, Shankey TV, Lubrano T, Mulhall JP. Inhibition of Peyronie's plaque fibroblast proliferation by biologic agents. Int J Impot Res 2000;12(3 suppl):S25-31.
30. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 2002;14:397-405.
31. Halici Z, Suleyman H, Cadirci E. Effects of calcium channel blockers on hyaluronidase-induced capillary vascular permeability. Arch Pharm Res 2008;31:891-9.
32. Gomes B, Cabral MD, Gallard A, Savignac M, Paulet P, Druet P, Mariamé B, Moreau M, Leclerc C, Guéry JC, Pelletier L. Calcium channel blocker prevents T helper type 2 cell-mediated airway inflammation. Am J Respir Crit Care Med 2007;175:1117-24.
33. Oyanagui Y, Sato S. Inhibition by nilvadipine of ischemic and carrageenan paw edema as well as of superoxide radical production from neutrophils and xanthine oxidase. Arzneimittelforschung 1991;41:469-74.
34. Kouoh F, Gressier B, Dine T, Luyckx M, Brunet C, Ballester L, Cazin JC. Antioxidant effects and anti-elastase activity of the calcium antagonist nicardipine on activated human and rabbit neutrophils-a potential antiatherosclerotic property of calcium antagonists? Cardiovasc Drugs Ther 2002;16:515-20.
35. Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration for Peyronie's disease: A double-blind, placebo controlled trial. J Urol 2007;177:972-5.
36. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie's disease: A randomized single-blind, placebo-controlled study. Int Urol Nephrol 2009;41:467-71.
37. Vardi Y, Levine LA, Chen J, Hatzimouratidis K, Sohn M. Is there a place for conservative treatment in Peyronie's disease? J Sex Med 2009;6:903-9.